ArticleOncotarget2016

Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.

Xinan Sheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.